S Black

Summary

Affiliation: Kaiser Permanente Medical Center
Country: USA

Publications

  1. ncbi Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers
    S B Black
    Pediatric Vaccine Study Group, Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 16:53-8. 1997
  2. ncbi Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project
    S Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 16:500-3. 1997
  3. ncbi Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
    H R Shinefield
    Kaiser Permanente Pediatric Vaccine Study Center of Northern California, Oakland, USA
    Pediatr Infect Dis J 18:757-63. 1999
  4. ncbi Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team
    P Ray
    Northern California Kaiser Permanente Vaccine Study Center, Oakland, CA 94611 5714, USA
    JAMA 278:551-6. 1997
  5. ncbi Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group
    S Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 19:187-95. 2000
  6. ncbi Perspectives on the design and analysis of prelicensure trials: bridging the gap to postlicensure studies
    S Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Clin Infect Dis 33:S323-6. 2001
  7. ncbi Efficacy of pneumococcal conjugate vaccines in large scale field trials
    H R Shinefield
    Vaccine Study Center, Kaiser Permanente Vaccine Study Center, Oakland, CA 94611, USA
    Pediatr Infect Dis J 19:394-7. 2000
  8. ncbi Postmarketing evaluation of the safety and effectiveness of varicella vaccine
    S Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 18:1041-6. 1999
  9. ncbi Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente
    S Black
    Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaze 16th floor, Oakland, CA 94612, USA
    Vaccine 19:S83-6. 2000
  10. ncbi Epidemiology of pertussis
    S Black
    Kaiser Permanente Pediatric Vaccine Study Center, Oakland, CA 94611, USA
    Pediatr Infect Dis J 16:S85-9. 1997

Detail Information

Publications11

  1. ncbi Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers
    S B Black
    Pediatric Vaccine Study Group, Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 16:53-8. 1997
    ..To evaluate the safety and immunogenicity of the recombinant acellular pertussis-diphtheria-tetanus (aPDT) vaccine (C-aPDT, Chiron/Biocine)...
  2. ncbi Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project
    S Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 16:500-3. 1997
    ..To assess the level of increased risk, if any, of hospitalizations for aseptic meningitis after Jeryl-Lynn mumps strain measles-mumps-rubella (MMR) vaccine in the Vaccine Safety Datalink population...
  3. ncbi Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
    H R Shinefield
    Kaiser Permanente Pediatric Vaccine Study Center of Northern California, Oakland, USA
    Pediatr Infect Dis J 18:757-63. 1999
    ....
  4. ncbi Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team
    P Ray
    Northern California Kaiser Permanente Vaccine Study Center, Oakland, CA 94611 5714, USA
    JAMA 278:551-6. 1997
    ..A review by the Institute of Medicine found a possible relationship between rubella vaccination and chronic arthritis among women...
  5. ncbi Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group
    S Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 19:187-95. 2000
    ....
  6. ncbi Perspectives on the design and analysis of prelicensure trials: bridging the gap to postlicensure studies
    S Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Clin Infect Dis 33:S323-6. 2001
    ....
  7. ncbi Efficacy of pneumococcal conjugate vaccines in large scale field trials
    H R Shinefield
    Vaccine Study Center, Kaiser Permanente Vaccine Study Center, Oakland, CA 94611, USA
    Pediatr Infect Dis J 19:394-7. 2000
    ....
  8. ncbi Postmarketing evaluation of the safety and effectiveness of varicella vaccine
    S Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 18:1041-6. 1999
    ..The Oka strain of live attenuated varicella virus was licensed for use in healthy children in the United States in March, 1995. We report a postmarketing evaluation of the short term safety of this vaccine within Kaiser Permanente...
  9. ncbi Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente
    S Black
    Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaze 16th floor, Oakland, CA 94612, USA
    Vaccine 19:S83-6. 2000
    ..Vaccination of healthy infants would result in net savings for society if the vaccine cost less than $46 per dose, and net savings for the health care payer if the vaccine cost less than $18 per dose...
  10. ncbi Epidemiology of pertussis
    S Black
    Kaiser Permanente Pediatric Vaccine Study Center, Oakland, CA 94611, USA
    Pediatr Infect Dis J 16:S85-9. 1997
    ..pertussis infection to other household members, particularly infants and young children who are not adequately immunized...
  11. ncbi [Clinical effectiveness of seven-valent pneumococcal conjugate vaccine (Prevenar) against invasive pneumococcal diseases: prospects for children in France]
    S Black
    Northern California Kaiser Permanente, Oakland, Californie, USA
    Arch Pediatr 11:843-53. 2004
    ....